aleglitazar

Also known as R-1439, Ro-0728804

Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator) with affinity to PPARα and PPARγ, which was under development by Hoffmann–La Roche for the treatment of type II diabetes. It is no longer in phase III clinical trials.

Wikidata facts

Mass: 437.13

Show 3 more facts

chemical formula: C₂₄H₂₃NO₅S
isomeric SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)C[C@@H](C(=O)O)OC
canonical SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=C4C=CSC4=C(C=C3)CC(C(=O)O)OC

Sources (2)

via Wikidata · CC0

~1 min read

Article

1 sections

Contents

References

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477246742 | ImageFile = Aleglitazar.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (2S)-2-Methoxy-3-{4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophen-7-yl}propanoic acid | OtherNames = Ro-0728804, R-1439 |Section1= |Section2= |Section3= }}